Thalmann

B. Riley Financial Announces Offering of $150 Million Senior Notes Due 2028 and "BBB+" Rating from Egan-Jones

Retrieved on: 
Friday, July 30, 2021
Credit rating agencies, Finance, Financial markets, Service companies, Ladenburg Thalmann, Thalmann, S&P Global Ratings, Underwriting, Egan-Jones Ratings Company, Security

The Company expects to grant the underwriters a 30-day option to purchase additional senior notes in connection with the offering.

Key Points: 
  • The Company expects to grant the underwriters a 30-day option to purchase additional senior notes in connection with the offering.
  • B. Riley Financial and this issuance of notes both received an investment grade rating of BBB+ from Egan-Jones Ratings Company, an independent, unaffiliated rating agency.
  • B. Riley Securities, Janney Montgomery Scott, Ladenburg Thalmann and William Blair are acting as book-running managers for this offering.
  • B. Riley Financial provides collaborative solutions tailored to fit the capital raising and business advisory needs of its clients and partners.

Kaival Brands Announces Initiation of Trading on Nasdaq Under Ticker Symbol "KAVL"

Retrieved on: 
Thursday, July 29, 2021
Economy of New York City, NASDAQ, Thalmann, Finance, Service companies, New York City

"This is an exciting moment in our company's history, and we are thrilled to commence trading on The Nasdaq Capital Market effective today," said Niraj Patel, Founder and Chief Executive Officer of Kaival Brands.

Key Points: 
  • "This is an exciting moment in our company's history, and we are thrilled to commence trading on The Nasdaq Capital Market effective today," said Niraj Patel, Founder and Chief Executive Officer of Kaival Brands.
  • "We wish to thank BTIG, Maxim, Ladenburg Thalmann & Co, and a few others for their supportive efforts on our first day of trading on the Nasdaq.
  • Our company is built upon strong core values, and we believe Nasdaq is the right exchange to serve us and our shareholders," noted Eric Mosser, Chief Operating Officer of Kaival Brands.
  • Both Kaival Brands and Bidi Vapor are vehemently opposed to all illegal underage tobacco use, including ENDS use, by minors.

Helius Medical Technologies, Inc. to Present at Two Upcoming Investor Conferences in July

Retrieved on: 
Monday, July 12, 2021
Flies, Insects, Limoniidae, Helius, Ladenburg Thalmann, Medtech, Thalmann, Health technology

The Alliance Global Partners Virtual MedTech Summer Conference, which is being held virtually on July 29th.

Key Points: 
  • The Alliance Global Partners Virtual MedTech Summer Conference, which is being held virtually on July 29th.
  • A webcast of the Ladenburg Thalmann Healthcare Conference presentation will be provided under the Events section of the Helius Medical Technologies investor relations website at https://heliusmedical.com/index.php/investor-relations/events/upcoming-e... .
  • Helius Medical Technologies is a neurotech company focused on neurological wellness.
  • Westwicke on behalf of Helius Medical Technologies, Inc.

TG Therapeutics to Participate in the Ladenburg Thalmann 2021 Healthcare Conference

Retrieved on: 
Friday, July 9, 2021
Ladenburg Thalmann, Thalmann, Lluís Companys, Spanish politicians, Companies, Government of Spain

NEW YORK, July 09, 2021 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that Michael S. Weiss, the Companys Chairman and Chief Executive Officer, will participate in a fireside chat during the Ladenburg Thalmann 2021 Healthcare Conference being held virtually.

Key Points: 
  • NEW YORK, July 09, 2021 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that Michael S. Weiss, the Companys Chairman and Chief Executive Officer, will participate in a fireside chat during the Ladenburg Thalmann 2021 Healthcare Conference being held virtually.
  • The fireside chat is scheduled to take place on Wednesday, July 14, 2021 at 12:30 PM ET.
  • A live webcast of each presentation will be available on the Events page, located within the Investors & Media section, of the Companys website at https://ir.tgtherapeutics.com/events .
  • TG Therapeuticsis a fully-integrated, commercial stage biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for B-cell malignancies and autoimmune diseases.

Atlanticus Holdings Corporation Announces Closing of Over-Allotment Option in Connection with Offering of Series B Cumulative Perpetual Preferred Stock

Retrieved on: 
Thursday, July 8, 2021
Ladenburg Thalmann, Underwriting, Thalmann, NET, Finance, Companies, Service companies

The offering resulted in net proceeds of approximately $9.3 million after deducting underwriting discounts and commissions, but before deducting expenses and the structuring fee.

Key Points: 
  • The offering resulted in net proceeds of approximately $9.3 million after deducting underwriting discounts and commissions, but before deducting expenses and the structuring fee.
  • The Company expects to use the net proceeds of this offering for general corporate purposes, including the repurchase of common stock.
  • B. Riley Securities, Inc., Janney Montgomery Scott LLC, Ladenburg Thalmann & Co. Inc. and William Blair & Company acted as book-running managers for this offering.
  • Kingswood Capital Markets, division of Benchmark Investments, LLC, acted as lead manager for the offering.

OPKO Health to Present at the Ladenburg Thalmann Healthcare Conference

Retrieved on: 
Thursday, July 8, 2021
OPKO Health, Ladenburg Thalmann, Thalmann, NASDAQ, Finance, Service companies, Companies

MIAMI, July 08, 2021 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) today announced that management will be participating in the Ladenburg Thalmann Healthcare Conference being held virtually July 13-14, 2021.

Key Points: 
  • MIAMI, July 08, 2021 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) today announced that management will be participating in the Ladenburg Thalmann Healthcare Conference being held virtually July 13-14, 2021.
  • Management will be interviewed in a fireside chat format on Tuesday, July 13th at 8:30 a.m. Eastern time and will also be holding one-on-one virtual meetings with investors throughout the day.
  • OPKO is a multinational biopharmaceutical and diagnostics company that seeks to establish industry-leading positions in large, rapidly growing markets by leveraging its discovery, development, and commercialization expertise and novel and proprietary technologies.
  • For more information, visit www.opko.com .

Zymeworks to Present at Ladenburg Thalmann Healthcare Conference

Retrieved on: 
Thursday, July 8, 2021
Biotechnology, Pharmaceutical, Health, Clinical trials, Zymeworks, Companies, Thalmann

Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced that the Company will present at the upcoming Ladenburg Thalmann Healthcare Conference on July 14, 2021 at 4:00 p.m.

Key Points: 
  • Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced that the Company will present at the upcoming Ladenburg Thalmann Healthcare Conference on July 14, 2021 at 4:00 p.m.
  • The presentation will be webcast live and available for replay on Zymeworks website at http://ir.zymeworks.com/events-and-presentations .
  • Zymeworks is a clinical-stage biopharmaceutical company dedicated to the development of next-generation multifunctional biotherapeutics.
  • Zymeworks suite of therapeutic platforms and its fully integrated drug development engine enable precise engineering of highly differentiated product candidates.

Eyenovia to Participate in Two Upcoming Investor Conferences

Retrieved on: 
Wednesday, July 7, 2021
Ladenburg Thalmann, Ladenburg, Microdosing, Thalmann, Service companies, Companies

NEW YORK, July 07, 2021 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic company developing a pipeline of advanced therapeutics based on its proprietary microdose array print (MAP) platform technology, today announced that management will present a corporate overview and host one-one-one meetings at the Ladenburg Thalmann 2021 Healthcare Conference, being held virtually July 13-14, 2021, and host one-on-meetings at the William Blair Biotech Focus Conference 2021, being held virtually July 14-15, 2021.

Key Points: 
  • NEW YORK, July 07, 2021 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic company developing a pipeline of advanced therapeutics based on its proprietary microdose array print (MAP) platform technology, today announced that management will present a corporate overview and host one-one-one meetings at the Ladenburg Thalmann 2021 Healthcare Conference, being held virtually July 13-14, 2021, and host one-on-meetings at the William Blair Biotech Focus Conference 2021, being held virtually July 14-15, 2021.
  • Details of the Ladenburg presentation are below:

Vericel to Present at the Ladenburg Thalmann Healthcare Conference on Tuesday, July 13, 2021

Retrieved on: 
Wednesday, July 7, 2021
Vericel, Ladenburg Thalmann, Thalmann, NASDAQ, Medicine, Colangelo, Finance, Service companies, Companies

CAMBRIDGE, Mass., July 07, 2021 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Nick Colangelo, President and CEO, will present the latest company overview at the Ladenburg Thalmann Healthcare Conference.

Key Points: 
  • CAMBRIDGE, Mass., July 07, 2021 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Nick Colangelo, President and CEO, will present the latest company overview at the Ladenburg Thalmann Healthcare Conference.
  • The conference is being conducted in a virtual format and the presentation will take place on Tuesday, July 13, 2021, at 9:00 a.m. Eastern Time.
  • A live webcast of the presentation will be available on the Investor Relations section of the Vericel Corporation website at: http://investors.vcel.com .
  • Vericel is a leader in advanced therapies for the sports medicine and severe burn care markets.

Artelo Biosciences to Present at the 2021 Ladenburg Thalmann Healthcare Conference on July 14th

Retrieved on: 
Wednesday, July 7, 2021
Thalmann

LA JOLLA, Calif., July 07, 2021 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (NASDAQ: ARTL ), a clinical stage biopharmaceutical company focused on the development of therapeutics that target lipid signaling pathways, including the endocannabinoid system, today announced that management will be presenting and hosting 1x1 meetings during the Ladenburg Thalmann Healthcare Conference taking place virtually July 13-14, 2021.

Key Points: 
  • LA JOLLA, Calif., July 07, 2021 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (NASDAQ: ARTL ), a clinical stage biopharmaceutical company focused on the development of therapeutics that target lipid signaling pathways, including the endocannabinoid system, today announced that management will be presenting and hosting 1x1 meetings during the Ladenburg Thalmann Healthcare Conference taking place virtually July 13-14, 2021.
  • Artelo is rapidly advancing a portfolio of broadly applicable product candidates designed to address significant unmet needs in multiple diseases and conditions, including anorexia, cancer, PTSD, pain, and inflammation.
  • Led by proven biopharmaceutical executives collaborating with highly respected researchers and technology experts, the San Diego-based company applies leading edge scientific, regulatory, and commercial discipline to develop high-impact therapies.
  • Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this press release.